Print this page    •   Back to Web version of article

New Anti-HIV Drugs Receive FDA Approval

October 2003

Three anti-HIV drugs have recently been approved by the Food and Drug Administration, including one in a new class called fusion or entry inhibitor. Each adds something unique to the arsenal of therapies to treat HIV infection. The three include:

Drug NameTrade NameCompanyDrug Class
T-20, enfuvirtideFuzeonHoffman La-Roche, Trimerisentry inhibitor
FTC, emtricitabineEmtrivaGileadnucleoside analog reverse transcriptase inhibitor
AtazanavirReyatazBristol-Myers Squibbprotease inhibitor

The following articles highlight information on each of the newly approved drugs and provide a discussion on how they fit into the arsenal of existing drugs.

Back to the Project Inform Perspective October 2003 contents page.

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.